Phase 1 Trial of HRS-1635 for Relapsed B-Cell Blood Cancers
Part of Blood & lymphatic, Cancer clinical trials.
This early-stage trial tests a new drug called HRS-1635 in patients with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to previous treatment. The goal is to find the right dose and understand how well and safely the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- Your cancer is a B-cell type (like lymphoma or leukemia) that has returned or stopped responding to prior treatment
- You are in good enough health to care for yourself with minimal help (ECOG 0-1)
- You do not have cancer spread to the brain or spinal cord
- You agree to use reliable birth control during the study if you can have children, and are not pregnant or breastfeeding
- You can swallow pills and do not have serious stomach or digestion problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
This early study (Phase 1) tests whether HRS-1167 can be given safely to people with advanced solid tumors. It also looks for early signs of activity, especially in cancers with HRR gene mutations (like ovarian, breast, pancreatic, and prostate cancers).
This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.
This study tests a new therapy called RS001 for people with B-cell lymphoma or B-cell leukemia that has not gotten better or has returned after treatment. It targets a marker called CD19 on cancer cells, and the goal is to see if it can help control the cancer.
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
Hear when a new B-cell Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.